Reuters: U.S. OKs Novartis Gleevac to reduce recurring cancer

[NaDiNe]

U.S. OKs Novartis Gleevac to reduce recurring cancer
      

WASHINGTON (Reuters) - U.S. health regulators have approved Novartis' drug Gleevac to reduce the risk of cancer recurring in patients with a rare type of stomach cancer, Novartis said on Friday.<div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login